Lightspeed Venture Partners, a venture capital firm, Vida Ventures, a next-generation life sciences investment firm, and MPM Capital, a biotechnology investment firm, led a $51m Series A round in Protego Biopharma, a preclinical-stage biotechnology company. “Protego is building on compelling science to develop small molecule therapeutics targeting protein misfolding, which is increasingly recognized as an underlying cause in many chronic degenerative diseases, and an area with enormous unmet medical need. We are thrilled to partner with a world-class investor syndicate during this pivotal stage as we accelerate the science from research to potentially delivering impactful medicines for patients,” Richard Labaudinière, Protego President and Chief Executive Officer.